Dreuil-lès-Amiens, France
Dreuil-lès-Amiens, France

Time filter

Source Type

TORONTO, ON--(Marketwired - February 17, 2017) - Axiom Real-Time Metrics, the premier provider of eClinical software solutions and services to small to mid-sized life sciences organizations, will be exhibiting at the Outsourcing in Clinical Trials event on the West Coast taking place in Burlingame, California on February 22-23, 2017. Axiom invites attendees to join them for gourmet coffee and a conversation at Booth 36. OCT West 2017 will bring together over 700 clinical professionals, including senior level executives from the pharmaceutical, biotech, and medical device sectors to discuss clinical outsourcing strategies and address key challenges within clinical operations. Axiom's Fusion eClinical suite and the unified modules Randomization, Inventory Management and Safety Management will be showcased at the conference. "Our team is excited to meet with attendees and share information about the benefits and value of our award winning product suite. Fusion delivers powerful, enterprise level software made for small to mid-size organizations. We provide a truly Unified eClinical suite and are always excited to share and illustrate what this distinction of being 'Truly Unified' really means and what sets us apart," says Andrew Schachter CEO and Founder. Christopher Kata, Axiom's CIO further offers, "Fusion, Axiom's product suite has been engineered with our design & programming teams, and directed through years of client input. All of our technology is delivered from a single source. We provide our 'peerless' Unified product and services to leading edge life science organizations around the world, and, true to our Mission we are partners in this journey together. This means that it eliminates having a separate EDC, randomization and adjudication vendor -- Fusion does it all!" Headquartered in Toronto, Canada, Axiom delivers intuitive, powerful and cost-effective eClinical solutions and services focused around your entire study. Services include: DM, Biostatistics and Pharmacovigilance. Axiom's eClinical suite, Fusion, delivers a powerful range of innovative end-user focused, unified functionality and 15 modules. Axiom serves as the Connected Hub for your entire clinical study data and operational needs. Fusion Delivers: EDC, DM, IWRS, CTMS, Inventory Management, IVR, Patient Portal, AE/SAE Tracking, Safety Database, Central Lab, Imaging, eTMF, and 24/7 Project and Clinical Data Reporting. For more information, please visit http://www.axiommetrics.com/.


News Article | March 1, 2017
Site: www.businesswire.com

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, is pleased to announce the appointments of Françoise Bono, PhD, to the role of Chief Scientific Officer and Olivier de Beaumont, MD, MBA, to the role of Chief Medical Officer. Their very specialized expertise will enable the Company to carry out its various projects, notably development activities on AsiDNA™, a first-in-class molecule acting as a tumor cell DNA repair inhibitor, as well as ongoing work to demonstrate belinostat’s potential in association with other anti-cancer agents in various types of tumor. It also represents a key asset just months before the interim results of the Livatag® Phase III trial. “Françoise and Olivier bring Onxeo a rare combination of extensive experience in the development of new treatments and an in-depth understanding of a biotech business model," commented Judith Greciet, Chief Executive Officer of Onxeo. "As a biotech company, our challenge is to bring our programs to major value inflection points as rapidly as possible on the basis of pertinent and attractive data, and thus drive the Company’s value. This is particularly important for AsiDNA™, which has substantial potential and for which the preclinical and clinical data generated over the coming months will be pivotal within this context. Francoise and Olivier’s arrival to lead our thought process and head our teams represents an undeniable asset for the implementation of our strategy." Previously, Françoise Bono spent over 25 years with Sanofi and Evotec and was, until late 2016, Evotec Executive Vice-President, Oncology. A prominent cancer biologist, she has brought several innovative compounds from early clinical development through to IND filing and Phase I trials. Françoise Bono has led over 20 major projects, notably in the field of immune-oncology, and developed extensive experience in science, people management and project leadership and evaluation, as well as recognized expertise in translational and development strategy in oncology. Françoise Bono received her PhD in Cellular Biology from Toulouse University. “I am delighted to be able to contribute to the development of Onxeo, which has successfully put together a promising and diverse portfolio based on innovative approaches liable to be a paradigm shift in the treatment of cancer. This is, for example, the case for the DNA repair inhibition technology that is behind AsiDNA™ and is one of the most exciting and promising of these novel approaches,” declared Françoise Bono. Since 2005, Olivier de Beaumont was with Stallergenes Greer as Senior Vice President, Head of Global Clinical Development, Pharmacovigilance and Medical Affairs, and a member of the Executive Committee. Prior to that, he led various clinical development programs and strategic marketing activities at Quintiles and Aventis, addressing a wide range of therapeutic areas and leading teams, notably in oncology. Dr. de Beaumont is a medical doctor and also holds a MBA from ESCP Business School and a Masters degree in Public Health & Health Economics. “I am thrilled to be joining Onxeo at this critical and transformative stage, and am extremely impressed by their tremendous drive to become an innovation engine in oncology. I am proud to be joining this experienced and dedicated team to help develop pioneering solutions that will address the unmet needs of cancer patients,” said Olivier de Beaumont. Prior to these appointments, preclinical and clinical operations were a single department. Former CSO Graham Dixon left the Company to pursue other opportunities. Under this new structure, Françoise Bono and her team will now focus on preclinical activities in collaboration with Olivier de Beaumont’s teams, who will henceforth be responsible for clinical development. Both Dr. Bono and Dr. de Beaumont are members of the Executive Committee and will be active participants in the Company’s strategic planning, partnering discussions, and presentations to investors and other key stakeholders. Onxeo is a biotechnology company developing innovative drugs for the treatment of orphan diseases in oncology, driven by high therapeutic demand in one of the fastest growing segments of the pharmaceutical industry. Onxeo’s objective is to become a major international player in the field of rare cancers. Its growth strategy is founded on the development of innovative, effective, and safe drugs based on breakthrough technologies that can make a real difference in the treatment of orphan oncology diseases and considerably improve the quality of life of patients affected by rare or resistant cancers. Onxeo’s comprehensive portfolio features a broad orphan oncology pipeline, with 3 major products in several on-going preclinical and clinical programs, alone or in combination for various cancer indications. The Company is headquartered in Paris, France with offices in Denmark and in New York, and has approximately 60 employees. Onxeo is listed on Euronext in Paris, France and Nasdaq Copenhagen, Denmark (Ticker: ONXEO, ISIN Code: FR0010095596). This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2015 Reference Document filed with the AMF on April 29, 2016, which is available on the AMF website (http://www.amf-france.org) or on the company’s website (www.onxeo.com).


North America region held the largest share of the pharmacovigilance and drug safety software market in 2014. However, Asian and Latin American countries symbolize high growth markets. This is owing to a rise in research outsourcing by pharmaceutical giants and growing public and private investments in pharmaceutical R&D in these emerging nations. The global pharmacovigilance and drug safety software market is expected to grow at a CAGR of 6.5% from 2014 to 2019. Complete report on Pharmacovigilance and Drug Safety Software Market spread across 210 Pages, Profiling 10 Companies and Supported with 74 Tables and 87 Figures is now available at http://www.reportsnreports.com/reports/354423-pharmacovigilance-and-drug-safety-software-market-by-functionality-adverse-event-reporting-fully-integrated-software-delivery-mode-on-premise-on-demand-cloud-based-saas-end-user-pharma-biotech-companies-cros-bpos-global-forecast-to-2019.html . In this report, the global pharmacovigilance and drug safety software market has been classified into four segments on the basis of functionality, namely, adverse event reporting software, drug safety audits software, issue tracking software, and fully integrated software. The global pharmacovigilance and drug safety software market is segmented into two segments on the basis of delivery mode, namely, on-premise delivery mode and on-demand/cloud based (SaaS) delivery mode. The global pharmacovigilance and drug safety software market is also segmented on the basis of end users including pharma and biotech companies, contract research organizations (CROs), business process outsourcing (BPO) firms, and other pharmacovigilance service providers.Comprehensive information about lucrative emerging markets. The report analyzes the markets for various pharmacovigilance and drug safety software across geographies. Interested in this New Research Study the Sample Copy of this research is Available Now The global pharmacovigilance and drug safety software market comprises large number of small and mid-size software developers and service providers. As of 2014, the global pharmacovigilance and drug safety software market was dominated by Oracle Corporation (U.S.). New service launches; agreements, and partnerships;software developments; and geographical expansions are some of the major strategies adopted by most of the market players to achieve growth in the pharmacovigilance and drug safety software market. Some of the key players in the global pharmacovigilance software market include ArisGlobal (U.S.), Ennov Solutions Inc. (U.S.), EXTEDO GmbH (U.S.), Online Business Applications, Inc. (U.S.), Oracle Corporation (U.S.), Sarjen Systems Pvt. Ltd (India), Sparta Systems, Inc. (U.S.), and United BioSource Corporation (U.S.), among others. Click now for more Details, Queries and Discount this study “Pharmacovigilance and Drug Safety Software Market by Functionality (Adverse Event Reporting, Fully Integrated Software), Delivery Mode (On-premise, On-demand/Cloud based (SAAS)), End-user (Pharma & Biotech Companies, CROs, BPOs) - Global Forecast to 2019” report @ http://www.reportsnreports.com/contacts/discount.aspx?name=354423 . Thus, growing complexity related to drug safety regulations is expected to drive the growth of the market during the forecast period. New service launches; agreements, and partnerships; software developments; and geographical expansions are some of the key strategies adopted by most of the market players to achieve growth in the pharmacovigilance software market. Explore more reports on Healthcare at http://www.reportsnreports.com/market-research/healthcare/ .


RALEIGH, N.C., Feb. 22, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to IV contract research organization, today announced expansion of its Functional Service Provider (FSP) service offering to include investigator payment processing, leveraging  the Company’s extensive expertise and delivery of  customized solutions in this area as well as insights gained from its industry-recognized site relationships. The addition of investigator payment processing to the Company’s FSP offering builds on its nearly 20 years of experience in meeting the needs of biopharmaceutical customers worldwide for standalone outsourced services under an FSP model, including Data Management, Medical Writing, Safety and Pharmacovigilance, and Site Contracts. “INC’s long history in working under the FSP business model, along with our proven track record in delivery of customized payment processing solutions for clinical research sites, are combining to create an exciting new offering for our customers,” said Tara Fitzgerald, President, Clinical Development Services and Head of the Company’s FSP offering. “We look forward to meeting the strong customer demand for services in this area while continuing to offer our customers a broad range of solutions that fit the way they want to work today — whether it be via a functional or full-service outsourcing model or both.” Delivery of INC’s Investigator Payment FSP services will be provided through a dedicated business unit led by Victoria Moore, Vice President, Investigator Payments, with hub locations in Raleigh, NC, US; Camberley, UK; and Gurgaon, India. The Company currently is providing Investigator Payment services for several large customers under both the FSP and full-service models. INC is leveraging the Medidata Payments Cloud, the only global site payment technology driven by an integrated Electronic Data Capture (EDC) and Clinical Trial Management System (CTMS), as the foundation for its offering. Medidata Payments automates the clinical site payment workflow, processing high volumes of invoices and complex payment requests quickly and accurately. Streamlined, on-time, global investigator payments traditionally have been overlooked in the CRO industry as many specialized investigator payment providers lack the resources, technology and global payment execution. Leveraging the insights gained from its strong site relationships across the globe, INC was able to further improve its own processing of investigator payments and in turn offer improved and streamlined investigator payment processing solutions to customers. Functional service provision has become an increasing and important model to biopharmaceutical customers worldwide for outsourcing of clinical development services. Services typically outsourced under an FSP model include high-volume clinical development tasks that are repetitive and duplicated across many projects. INC Research offers customized FSP solutions to customers, including tactical outsourcing of certain functions on a specific trial as well as strategic outsourcing of an entire department or function such as investigator payment processing. The Company's FSP model uses strategic commitment and performance-based measures to improve productivity in key service areas. The end result is greater cost predictability and quality delivery of consistent services. About INC Research INC Research (Nasdaq:INCR) is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.  Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market.  The Company was ranked “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey.  INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 110 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research.


RALEIGH, N.C., Feb. 22, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to IV contract research organization, today announced expansion of its Functional Service Provider (FSP) service offering to include investigator payment processing, leveraging  the Company’s extensive expertise and delivery of  customized solutions in this area as well as insights gained from its industry-recognized site relationships. The addition of investigator payment processing to the Company’s FSP offering builds on its nearly 20 years of experience in meeting the needs of biopharmaceutical customers worldwide for standalone outsourced services under an FSP model, including Data Management, Medical Writing, Safety and Pharmacovigilance, and Site Contracts. “INC’s long history in working under the FSP business model, along with our proven track record in delivery of customized payment processing solutions for clinical research sites, are combining to create an exciting new offering for our customers,” said Tara Fitzgerald, President, Clinical Development Services and Head of the Company’s FSP offering. “We look forward to meeting the strong customer demand for services in this area while continuing to offer our customers a broad range of solutions that fit the way they want to work today — whether it be via a functional or full-service outsourcing model or both.” Delivery of INC’s Investigator Payment FSP services will be provided through a dedicated business unit led by Victoria Moore, Vice President, Investigator Payments, with hub locations in Raleigh, NC, US; Camberley, UK; and Gurgaon, India. The Company currently is providing Investigator Payment services for several large customers under both the FSP and full-service models. INC is leveraging the Medidata Payments Cloud, the only global site payment technology driven by an integrated Electronic Data Capture (EDC) and Clinical Trial Management System (CTMS), as the foundation for its offering. Medidata Payments automates the clinical site payment workflow, processing high volumes of invoices and complex payment requests quickly and accurately. Streamlined, on-time, global investigator payments traditionally have been overlooked in the CRO industry as many specialized investigator payment providers lack the resources, technology and global payment execution. Leveraging the insights gained from its strong site relationships across the globe, INC was able to further improve its own processing of investigator payments and in turn offer improved and streamlined investigator payment processing solutions to customers. Functional service provision has become an increasing and important model to biopharmaceutical customers worldwide for outsourcing of clinical development services. Services typically outsourced under an FSP model include high-volume clinical development tasks that are repetitive and duplicated across many projects. INC Research offers customized FSP solutions to customers, including tactical outsourcing of certain functions on a specific trial as well as strategic outsourcing of an entire department or function such as investigator payment processing. The Company's FSP model uses strategic commitment and performance-based measures to improve productivity in key service areas. The end result is greater cost predictability and quality delivery of consistent services. About INC Research INC Research (Nasdaq:INCR) is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.  Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market.  The Company was ranked “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey.  INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 110 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research.


RALEIGH, N.C., Feb. 22, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to IV contract research organization, today announced expansion of its Functional Service Provider (FSP) service offering to include investigator payment processing, leveraging  the Company’s extensive expertise and delivery of  customized solutions in this area as well as insights gained from its industry-recognized site relationships. The addition of investigator payment processing to the Company’s FSP offering builds on its nearly 20 years of experience in meeting the needs of biopharmaceutical customers worldwide for standalone outsourced services under an FSP model, including Data Management, Medical Writing, Safety and Pharmacovigilance, and Site Contracts. “INC’s long history in working under the FSP business model, along with our proven track record in delivery of customized payment processing solutions for clinical research sites, are combining to create an exciting new offering for our customers,” said Tara Fitzgerald, President, Clinical Development Services and Head of the Company’s FSP offering. “We look forward to meeting the strong customer demand for services in this area while continuing to offer our customers a broad range of solutions that fit the way they want to work today — whether it be via a functional or full-service outsourcing model or both.” Delivery of INC’s Investigator Payment FSP services will be provided through a dedicated business unit led by Victoria Moore, Vice President, Investigator Payments, with hub locations in Raleigh, NC, US; Camberley, UK; and Gurgaon, India. The Company currently is providing Investigator Payment services for several large customers under both the FSP and full-service models. INC is leveraging the Medidata Payments Cloud, the only global site payment technology driven by an integrated Electronic Data Capture (EDC) and Clinical Trial Management System (CTMS), as the foundation for its offering. Medidata Payments automates the clinical site payment workflow, processing high volumes of invoices and complex payment requests quickly and accurately. Streamlined, on-time, global investigator payments traditionally have been overlooked in the CRO industry as many specialized investigator payment providers lack the resources, technology and global payment execution. Leveraging the insights gained from its strong site relationships across the globe, INC was able to further improve its own processing of investigator payments and in turn offer improved and streamlined investigator payment processing solutions to customers. Functional service provision has become an increasing and important model to biopharmaceutical customers worldwide for outsourcing of clinical development services. Services typically outsourced under an FSP model include high-volume clinical development tasks that are repetitive and duplicated across many projects. INC Research offers customized FSP solutions to customers, including tactical outsourcing of certain functions on a specific trial as well as strategic outsourcing of an entire department or function such as investigator payment processing. The Company's FSP model uses strategic commitment and performance-based measures to improve productivity in key service areas. The end result is greater cost predictability and quality delivery of consistent services. About INC Research INC Research (Nasdaq:INCR) is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.  Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market.  The Company was ranked “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey.  INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 110 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research.


RALEIGH, N.C., Feb. 22, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to IV contract research organization, today announced expansion of its Functional Service Provider (FSP) service offering to include investigator payment processing, leveraging  the Company’s extensive expertise and delivery of  customized solutions in this area as well as insights gained from its industry-recognized site relationships. The addition of investigator payment processing to the Company’s FSP offering builds on its nearly 20 years of experience in meeting the needs of biopharmaceutical customers worldwide for standalone outsourced services under an FSP model, including Data Management, Medical Writing, Safety and Pharmacovigilance, and Site Contracts. “INC’s long history in working under the FSP business model, along with our proven track record in delivery of customized payment processing solutions for clinical research sites, are combining to create an exciting new offering for our customers,” said Tara Fitzgerald, President, Clinical Development Services and Head of the Company’s FSP offering. “We look forward to meeting the strong customer demand for services in this area while continuing to offer our customers a broad range of solutions that fit the way they want to work today — whether it be via a functional or full-service outsourcing model or both.” Delivery of INC’s Investigator Payment FSP services will be provided through a dedicated business unit led by Victoria Moore, Vice President, Investigator Payments, with hub locations in Raleigh, NC, US; Camberley, UK; and Gurgaon, India. The Company currently is providing Investigator Payment services for several large customers under both the FSP and full-service models. INC is leveraging the Medidata Payments Cloud, the only global site payment technology driven by an integrated Electronic Data Capture (EDC) and Clinical Trial Management System (CTMS), as the foundation for its offering. Medidata Payments automates the clinical site payment workflow, processing high volumes of invoices and complex payment requests quickly and accurately. Streamlined, on-time, global investigator payments traditionally have been overlooked in the CRO industry as many specialized investigator payment providers lack the resources, technology and global payment execution. Leveraging the insights gained from its strong site relationships across the globe, INC was able to further improve its own processing of investigator payments and in turn offer improved and streamlined investigator payment processing solutions to customers. Functional service provision has become an increasing and important model to biopharmaceutical customers worldwide for outsourcing of clinical development services. Services typically outsourced under an FSP model include high-volume clinical development tasks that are repetitive and duplicated across many projects. INC Research offers customized FSP solutions to customers, including tactical outsourcing of certain functions on a specific trial as well as strategic outsourcing of an entire department or function such as investigator payment processing. The Company's FSP model uses strategic commitment and performance-based measures to improve productivity in key service areas. The end result is greater cost predictability and quality delivery of consistent services. About INC Research INC Research (Nasdaq:INCR) is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.  Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market.  The Company was ranked “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey.  INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 110 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research.


News Article | December 13, 2016
Site: globenewswire.com

Ocean View, Delaware, Dec. 13, 2016 (GLOBE NEWSWIRE) -- Pharmacovigilance Market size is expected to exceed USD 8 billion by 2024; according to a new research report by Global Market Insights, Inc. Growing number of adverse drug reactions (ADRs) coupled with increasing prevalence of chronic diseases will drive global pharmacovigilance market size. Furthermore, growing geriatric population base is associated with increased drug consumption for treatment of chronic diseases such as diabetes, oncology cardiovascular and respiratory disorders. Rising demand for drugs has driven the need for new drug development through clinical trials. Pharmaceutical companies are collaborating with CROs to streamline R&D, medical writing, manufacturing operations, clinical data management and other pharmacovigilance activities to achieve greater efficiency at reduced cost. Outsourcing should enable better regulatory compliance, higher productivity and improved strategic outcomes spurring pharmacovigilance market growth. Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/853 Increasing number of National pharmacovigilance centers across the globe along with rising patient awareness regarding adverse drug events will stimulate global pharmacovigilance market growth. However, lack of skilled professionals and risk associated with data security and web-based drug sales will hamper business expansion. The phase IV clinical trial market size was valued more than USD 2 billion in 2015 and is expected to grow at over 10% by 2024. Phase IV studies ensure that restrictions could be imposed on a drug being sold depending on its safety performance. Contract outsourcing market size was valued over USD 1 billion in 2015, poised to grow at 12.2% from 2016 to 2024 and surpass USD 4 billion by 2024. Contract outsourcing reduces overall economic losses linked with drug approval delays and trial failures. It is widely opted by companies to avoid huge investments and delegate such activities to specialized firms in this area. U.S. pharmacovigilance market size was valued at more than USD 1 billion in 2015, with expectations to grow at 10.7% over the forecast period, owing to favorable governmental regulations, huge clinical trial volume and presence of large scale research companies. Additionally, growing patient concerns related to the drug safety and rising adverse drug events related mortality rates will positively impact pharmacovigilance market share. Spain pharmacovigilance market size was valued over USD 230 million in 2015 and should witness 10.2% CAGR from 2016 to 2024, to surpass USD 550 million by 2024. Rising demand for new drug development, growing geriatric population and increasing outsourcing by pharmaceutical companies should fuel regional industry growth. India pharmacovigilance market growth was more than 14% from 2016 to 2024, and expected to reach USD 668 million by 2024. The strong and robust growth is attributed to increasing number of clinical trials conducted across Asian countries, owing to low cost trial advantage over developed countries. Key industry players such as Quintiles offer literature monitoring, safety aggregate reporting, benefit risk management, analytics and signal detection services. Synowledge offer signal detection services, which help clinical experts determine medical significance with the use of hi-tech visualization techniques. Many industry participants are focusing on outsourcing pharmacovigilance services as a feasible cost reduction avenue. Outsourcing helps achieve better pharmacovigilance through regulatory compliance, better quality, enhanced productivity and improved strategic outcomes. Browse key industry insights spread across 111 pages with 66 market data tables & 6 figures& charts from the report, “Pharmacovigilance Market Size By Clinical Trial Phase (Preclinical, Phase I, Phase II, Phase III, Phase IV), By Service Provider (In-house, Contract outsourcing) Industry Analysis Report, Regional Outlook (U.S., Canada, UK, Germany, Spain, Italy, France, China, Japan, India, Australia, Argentina, Brazil, Mexico, South Africa, Saudi Arabia, UAE, Qatar), Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2024” in detail along with the table of contents: Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/853 Pharmacovigilance market research report includes in-depth industry coverage with estimates & forecast in terms of revenue in USD million from 2012 to 2024 , for the following segments: The above information is provided for the following regions and countries: Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.


News Article | December 13, 2016
Site: globenewswire.com

Ocean View, Delaware, Dec. 13, 2016 (GLOBE NEWSWIRE) -- Pharmacovigilance Market size is expected to exceed USD 8 billion by 2024; according to a new research report by Global Market Insights, Inc. Growing number of adverse drug reactions (ADRs) coupled with increasing prevalence of chronic diseases will drive global pharmacovigilance market size. Furthermore, growing geriatric population base is associated with increased drug consumption for treatment of chronic diseases such as diabetes, oncology cardiovascular and respiratory disorders. Rising demand for drugs has driven the need for new drug development through clinical trials. Pharmaceutical companies are collaborating with CROs to streamline R&D, medical writing, manufacturing operations, clinical data management and other pharmacovigilance activities to achieve greater efficiency at reduced cost. Outsourcing should enable better regulatory compliance, higher productivity and improved strategic outcomes spurring pharmacovigilance market growth. Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/853 Increasing number of National pharmacovigilance centers across the globe along with rising patient awareness regarding adverse drug events will stimulate global pharmacovigilance market growth. However, lack of skilled professionals and risk associated with data security and web-based drug sales will hamper business expansion. The phase IV clinical trial market size was valued more than USD 2 billion in 2015 and is expected to grow at over 10% by 2024. Phase IV studies ensure that restrictions could be imposed on a drug being sold depending on its safety performance. Contract outsourcing market size was valued over USD 1 billion in 2015, poised to grow at 12.2% from 2016 to 2024 and surpass USD 4 billion by 2024. Contract outsourcing reduces overall economic losses linked with drug approval delays and trial failures. It is widely opted by companies to avoid huge investments and delegate such activities to specialized firms in this area. U.S. pharmacovigilance market size was valued at more than USD 1 billion in 2015, with expectations to grow at 10.7% over the forecast period, owing to favorable governmental regulations, huge clinical trial volume and presence of large scale research companies. Additionally, growing patient concerns related to the drug safety and rising adverse drug events related mortality rates will positively impact pharmacovigilance market share. Spain pharmacovigilance market size was valued over USD 230 million in 2015 and should witness 10.2% CAGR from 2016 to 2024, to surpass USD 550 million by 2024. Rising demand for new drug development, growing geriatric population and increasing outsourcing by pharmaceutical companies should fuel regional industry growth. India pharmacovigilance market growth was more than 14% from 2016 to 2024, and expected to reach USD 668 million by 2024. The strong and robust growth is attributed to increasing number of clinical trials conducted across Asian countries, owing to low cost trial advantage over developed countries. Key industry players such as Quintiles offer literature monitoring, safety aggregate reporting, benefit risk management, analytics and signal detection services. Synowledge offer signal detection services, which help clinical experts determine medical significance with the use of hi-tech visualization techniques. Many industry participants are focusing on outsourcing pharmacovigilance services as a feasible cost reduction avenue. Outsourcing helps achieve better pharmacovigilance through regulatory compliance, better quality, enhanced productivity and improved strategic outcomes. Browse key industry insights spread across 111 pages with 66 market data tables & 6 figures& charts from the report, “Pharmacovigilance Market Size By Clinical Trial Phase (Preclinical, Phase I, Phase II, Phase III, Phase IV), By Service Provider (In-house, Contract outsourcing) Industry Analysis Report, Regional Outlook (U.S., Canada, UK, Germany, Spain, Italy, France, China, Japan, India, Australia, Argentina, Brazil, Mexico, South Africa, Saudi Arabia, UAE, Qatar), Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2024” in detail along with the table of contents: Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/853 Pharmacovigilance market research report includes in-depth industry coverage with estimates & forecast in terms of revenue in USD million from 2012 to 2024 , for the following segments: The above information is provided for the following regions and countries: Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.


News Article | February 15, 2017
Site: www.prweb.com

APCER Life Sciences, Inc., the truly global provider of safety, medical, regulatory and technology services, and Advera Health Analytics, Inc., a leading healthcare informatics company, today announced a wide-ranging partnership. Under the terms of their agreement, APCER Life Sciences will become an exclusive authorized reseller of Advera’s powerful Evidex™ platform for signal detection, comparative analysis, and outcomes research, and will integrate Evidex into its services offerings for drug safety and medical affairs. “Advera Health has built the big data solution that pharmacovigilance professionals have been waiting for – an easy-to-use platform to analyze, visualize, and find meaning in the accelerating volume of safety cases that are diligently documented and reported every day during development and post-marketing,” said Suneet Walia, President and CEO of APCER Life Sciences. “We are proud to become an exclusive partner to Advera and equip our safety and outcomes scientists with the Evidex platform to enhance the value we bring to our clients in signal detection, comparative safety reviews, and market access research.” Advera’s Evidex™ is a scalable, simple-to-use, web-based data and analytics platform that provides comprehensive coverage on the safety profiles of both approved and clinical stage drugs. Evidex features peer-reviewed, proprietary analytics, focused on safety signal detection and management. Its analytics are built upon core data assets from curated clinical trial results, the FDA Adverse Event Reporting System (FAERS), and client-provided data. Additionally, direct downstream medical cost calculations and outcomes analyses allow the impact of a product’s safety profile to be effectively communicated to all stakeholders. APCER’s clients will have the opportunity to utilize Advera’s Evidex™ platform and advisory services to better identify, manage, and communicate safety risks. ”As a leader in its field, APCER Life Sciences has recognized that proactive signal management, comparative safety research, real-world evidence generation, and commercial planning support are the areas that represent the future for pharmacovigilance,” said Brian M. Overstreet, president and CEO of Advera Health Analytics. “We are very pleased to partner with APCER Life Sciences, whose deep expertise in this market will help to inform our future development and accelerate the roll out of our services to meet the growing demand within their client base.” The announcement of the partnership coincides with the opening of the DIA Pharmacovigilance and Risk Management Strategies conference in Washington, DC, an annual forum that brings together industry, academia, regulators, and patient representatives for thought-provoking sessions and candid discussion of common challenges. Representatives of APCER Life Sciences and Advera Health Analytics will be on hand through Wednesday to debut the partnership and discuss their solutions at Table 11 in the Exhibitor Ballroom. About APCER Life Sciences APCER Life Sciences is committed to improving health in partnership with its clients. It brings together safety, medical, regulatory, and technology resources to ensure that patients receive the safest, most effective therapies possible. To learn how APCER Life Sciences works together for better health, please follow the company on Twitter, LinkedIn, and Facebook; visit http://www.apcerls.com; and contact APCER at one of their global offices. About Advera Health Analytics Advera Health Analytics is a healthcare informatics company that improves patient outcomes and reduces systemic healthcare costs through the comprehensive analysis of drug evidence. Utilizing proprietary data-mining and analytics, Advera Health makes evidence accessible, actionable, and predictable. Advera Health provides solutions to enterprise markets including managed care organizations, health systems and hospitals, and the pharmaceutical industry. Please visit http://www.adverahealth.com as well as our newsroom, blog, Twitter, and LinkedIn pages for more information about the company.

Loading Pharmacovigilance collaborators
Loading Pharmacovigilance collaborators